Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Real-time Estimate Cboe BZX
Other stock markets
 03:27:27 2024-04-29 pm EDT 		5-day change 1st Jan Change
30.81 USD +2.46% Intraday chart for Supernus Pharmaceuticals, Inc. +3.84% +6.60%
Apr. 08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ
Apr. 08 Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830
CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
RE
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M
MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents
MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada
MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada
MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
CI
Knight Therapeutics in Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
MT
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling
MT
US Consumer group seeks stronger warnings on Botox, similar treatments
RE
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q3 Revenue $153.9M, vs. Street Est of $143.4M
MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023
CI
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
CI
Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device
CI
Supernus Resubmits New Drug Application for SPN-830 Apomorphine Infusion Device
MT
Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. News Supernus Pharmaceuticals, Inc.
  5. Highlights